Difference between revisions of "Bleomycin (Blenoxane)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Neutral chemotherapy" to "Category:Neutral") |
m |
||
| Line 10: | Line 10: | ||
*[[Adenocarcinoma of unknown primary]] | *[[Adenocarcinoma of unknown primary]] | ||
*[[Cutaneous basal cell carcinoma]] | *[[Cutaneous basal cell carcinoma]] | ||
| + | *[[Cutaneous squamous cell carcinoma]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 15: | Line 16: | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
| + | *[[Kaposi sarcoma]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Penile cancer]] | *[[Penile cancer]] | ||
*[[Post-transplant lymphoproliferative disorder]] | *[[Post-transplant lymphoproliferative disorder]] | ||
| − | |||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 56: | Line 56: | ||
[[Category:Cutaneous squamous cell carcinoma medications]] | [[Category:Cutaneous squamous cell carcinoma medications]] | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
| − | [[Category: | + | [[Category:Kaposi sarcoma medications]] |
[[Category:FDA approved in 1973]] | [[Category:FDA approved in 1973]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 15:23, 23 January 2020
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1][2]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Osteosarcoma
- Penile cancer
- Post-transplant lymphoproliferative disorder
- Testicular cancer
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[3]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/31/1973: Initial FDA approval
Also known as
- Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
References
- Drugs
- Intracavitary medications
- Intramuscular medications
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- DNA synthesis inhibitors
- Adenocarcinoma of unknown primary medications
- Cutaneous basal cell carcinoma medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Osteosarcoma medications
- Penile cancer medications
- Post-transplant lymphoproliferative disorder medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Kaposi sarcoma medications
- FDA approved in 1973
- WHO Essential Cancer Medicine